Academic Journal
Προβολή σε EDS

G-Quadruplex-Modular CpG Nanoplatform Drives Multi-Pathway Immunity for Abscopal Chemoimmunotherapy.

Λεπτομέρειες βιβλιογραφικής εγγραφής
Τίτλος: G-Quadruplex-Modular CpG Nanoplatform Drives Multi-Pathway Immunity for Abscopal Chemoimmunotherapy.
Συγγραφείς: Sun M; Beijing National Laboratory for Molecular Sciences (BNLMS), State Key Laboratory For Structural Chemistry of Unstable and Stable Species, Institute of Chemistry, Chinese Academy of Sciences, Beijing, China.; University of the Chinese Academy of Sciences (UCAS), Beijing, China.; Guangzhou Wondfo Biotech Co. Ltd., Guangzhou, China., Feng H; Beijing National Laboratory for Molecular Sciences (BNLMS), State Key Laboratory For Structural Chemistry of Unstable and Stable Species, Institute of Chemistry, Chinese Academy of Sciences, Beijing, China.; University of the Chinese Academy of Sciences (UCAS), Beijing, China., Sun X; Beijing National Laboratory for Molecular Sciences (BNLMS), State Key Laboratory For Structural Chemistry of Unstable and Stable Species, Institute of Chemistry, Chinese Academy of Sciences, Beijing, China.; University of the Chinese Academy of Sciences (UCAS), Beijing, China., Bai R; Beijing National Laboratory for Molecular Sciences (BNLMS), State Key Laboratory For Structural Chemistry of Unstable and Stable Species, Institute of Chemistry, Chinese Academy of Sciences, Beijing, China., Feng F; Beijing National Laboratory for Molecular Sciences (BNLMS), State Key Laboratory For Structural Chemistry of Unstable and Stable Species, Institute of Chemistry, Chinese Academy of Sciences, Beijing, China.; University of the Chinese Academy of Sciences (UCAS), Beijing, China., Li Q; Beijing National Laboratory for Molecular Sciences (BNLMS), State Key Laboratory For Structural Chemistry of Unstable and Stable Species, Institute of Chemistry, Chinese Academy of Sciences, Beijing, China.; University of the Chinese Academy of Sciences (UCAS), Beijing, China., Sun H; Beijing National Laboratory for Molecular Sciences (BNLMS), State Key Laboratory For Structural Chemistry of Unstable and Stable Species, Institute of Chemistry, Chinese Academy of Sciences, Beijing, China.; University of the Chinese Academy of Sciences (UCAS), Beijing, China., Yao L; Beijing National Laboratory for Molecular Sciences (BNLMS), State Key Laboratory For Structural Chemistry of Unstable and Stable Species, Institute of Chemistry, Chinese Academy of Sciences, Beijing, China.; University of the Chinese Academy of Sciences (UCAS), Beijing, China.
Πηγή: Advanced materials (Deerfield Beach, Fla.) [Adv Mater] 2026 Sep; Vol. 38 (54), pp. e72908. Date of Electronic Publication: 2026 Mar 25.
Τύπος έκδοσης: Journal Article
Γλώσσα: English
Στοιχεία περιοδικού: Publisher: Wiley-VCH Country of Publication: Germany NLM ID: 9885358 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1521-4095 (Electronic) Linking ISSN: 09359648 NLM ISO Abbreviation: Adv Mater Subsets: MEDLINE
Imprint Name(s): Publication: Sept. 3, 1997- : Weinheim : Wiley-VCH
Original Publication: Deerfield Beach, FL : VCH Publishers, 1989-
Ιατρικοί όροι (MeSH): Immunotherapy*/methods , Nanoparticles*/chemistry , G-Quadruplexes* , CpG Islands*, Doxorubicin/chemistry ; Doxorubicin/pharmacology ; Doxorubicin/therapeutic use ; Tumor Microenvironment/drug effects ; Toll-Like Receptor 9/metabolism ; Magnetic Iron Oxide Nanoparticles/chemistry ; Oligodeoxyribonucleotides/chemistry ; Animals ; Mice ; Cell Line, Tumor ; Female ; cGAS-STING Signaling Pathway ; Humans
Περίληψη: Conventional cancer immunotherapy suffers from insufficient immune activation, immunosuppressive tumor microenvironment (TME), and rapid CpG adjuvant degradation. To address these challenges, we developed a G-quadruplex (G4)-modular CpG nanoplatform named IONP-G4-DOX/IMT, which uses iron oxide nanoparticles (IONPs) as a stable structural and biocompatible core and G4 as a multifunctional hub. The rationally designed G4 module enables three synergistic functions encompassing enhanced CpG nuclease resistance for sustained TLR9 pathway activation, site-specific loading of doxorubicin (DOX) to trigger potent immunogenic cell death (ICD) and release tumor antigens, and IMT anchoring to activate the cGAS-STING pathway. These three processes are structurally coordinated and functionally synergistic, collectively driving robust dendritic cell maturation, boosting CD4+/CD8+ T cell infiltration, and reducing regulatory T cell accumulation. This cascade of immune modulation effectively reprograms the TME into an immune-permissive state. In murine 4T1 breast cancer models, IONP-G4-DOX/IMT achieves a primary tumor suppression rate of approximately 79.4%, with no significant systemic toxicity. More importantly, it elicits potent long-term antitumor immunity that inhibits contralateral tumor growth, offering a versatile and promising strategy for advanced abscopal chemoimmunotherapy.
(© 2026 Wiley‐VCH GmbH.)
References: A. Fesnak, C. June, and B. Levine, “Engineered T Cells: The Promise and Challenges of Cancer Immunotherapy,” Nature Reviews Cancer 16 (2016): 566–581, https://doi.org/10.1038/nrc.2016.97.
J. Del Paggio, “Cancer Immunotherapy and the Value of Cure,” Nature Reviews Clinical Oncology 15 (2018): 268–270, https://doi.org/10.1038/nrclinonc.2018.27.
J. Agudo and Y. Miao, “Stemness in Solid Malignancies: Coping With Immune Attack,” Nature Reviews Cancer 25 (2025): 27–40, https://doi.org/10.1038/s41568‐024‐00760‐0.
E. C. Morris, S. S. Neelapu, T. Giavridis, and M. Sadelain, “Cytokine Release Syndrome and Associated Neurotoxicity in Cancer Immunotherapy,” Nature Reviews Immunology 22 (2022): 85–96, https://doi.org/10.1038/s41577‐021‐00547‐6.
K. Aliazis, A. Christofides, R. Shah, et al., “The Tumor Microenvironment's Role in the Response to Immune Checkpoint Blockade,” Nature Cancer 6 (2015): 924–937, https://doi.org/10.1038/s43018‐025‐00986‐3.
D. Tang, M. Cui, J. Karges et al., “NIR‐II Photoactivatable Cobalt(III) Nanoparticles for Photoactivated Metal Chemo‐Immunotherapy,” Advanced Materials 38 (2026): e16008.
S. Zuo, H. Liu, G. Jiang, et al., “Responsive Photosensitizer Precursors Reverse Drug‐Induced Secondary Immunosuppression,” Journal of the American Chemical Society 147 (2025): 42825–42838.
J. Zou, C. Jiang, Q. Hu, et al., “Tumor Microenvironment‐Responsive Engineered Hybrid Nanomedicine for Photodynamic‐Immunotherapy via Multi‐Pronged Amplification of Reactive Oxygen Species,” Nature Communications 16 (2025): 424, https://doi.org/10.1038/s41467‐024‐55658‐0.
H. Zhao, L. Wang, S. Yang, et al., “Smart Energy‐Storing DNA Hydrogel for On‐Demand Laser‐Free Photoimmunotherapy of Melanoma,” Journal of the American Chemical Society 147 (2025): 21194–21208, https://doi.org/10.1021/jacs.5c06905.
R. Zhang, M. Chen, H. Zhou, et al., “Eliminating Radioresistance With a Magnetic Ion‐Generator by Simultaneously Augmenting DNA Damage and Diminishing Immunosuppression,” Advanced Materials 37 (2025): 2406378, https://doi.org/10.1002/adma.202406378.
J. Liu, C. Qu, Y. Liu, et al., “WDR4 Drives Tumour‐Associated Macrophage Reprogramming and Tumour Progression via Selective Translation and Membrane Cholesterol Efflux,” Nature Cell Biology 27 (2025): 2152–2166, doi.org/10.1038/s41556‐025‐01815‐6.
P. Z. Liang, L. L. Ren, Y. H. Yan, et al., “Activatable Photosensitizer Prodrug for Self‐Amplified Immune Therapy Via Pyroptosis,” Angewandte Chemie International Edition 64 (2025): 202419376, https://doi.org/10.1002/anie.202419376.
H. Huang, Q. S. Tong, Y. Chen, et al., “PAMAM‐Based Polymeric Immunogenic Cell Death Inducer To Potentiate Cancer Immunotherapy,” Journal of the American Chemical Society 146 (2024): 29189–29198, https://doi.org/10.1021/jacs.4c11636.
C. Glorieux, L. Cui, P. Zeng, X. Xia, and P. Huang, “Diverse Effects of Chemotherapeutic Agents on Immune Cell Function and Implications in Immunochemotherapy,” Cancer Communications 41 (2021): 432–435.
N. H. Park, W. Cheng, F. Lai, et al., “Addressing Drug Resistance in Cancer With Macromolecular Chemotherapeutic Agents,” Journal of the American Chemical Society 140 (2018): 4244–4252, https://doi.org/10.1021/jacs.7b11468.
B. Chabner and T. Roberts, “Chemotherapy and the War on Cancer,” Nature Reviews Cancer 5 (2005): 65–72, https://doi.org/10.1038/nrc1529.
L. Zhao, R. Zheng, X. Rao, et al., “Chemotherapy‐Enabled Colorectal Cancer Immunotherapy of Self‐Delivery Nano‐PROTACs by Inhibiting Tumor Glycolysis and Avoiding Adaptive Immune Resistance,” Advanced Science 11 (2024): 2309204, https://doi.org/10.1002/advs.202309204.
B. Feng, F. Zhou, B. Hou, et al., “Binary Cooperative Prodrug Nanoparticles Improve Immunotherapy by Synergistically Modulating Immune Tumor Microenvironment,” Advanced Materials 30 (2018): 1803001, https://doi.org/10.1002/adma.201803001.
T. S. Lau, L. K. Y. Chan, G. C. W. Man, et al., “Paclitaxel Induces Immunogenic Cell Death in Ovarian Cancer via TLR4/IKK2/SNARE‐Dependent Exocytosis,” Cancer Immunology Research 8 (2020): 1099–1111, https://doi.org/10.1158/2326‐6066.CIR‐19‐0616.
H. Wu, X. Sun, K. Li, et al., Advanced Science 12 (2025): 2409790.
C. Yang, S. Guo, K. Ye, et al., “A Trispecific Antibody Engaging T Cells with Tumour and Myeloid Cells Augments Antitumour Immunity,” Nature Biomedical Engineering (2025), doi.org/10.1038/s41551‐025‐01569‐4.
H. Abken, “CAR T Cell Therapies in Gastrointestinal Cancers: Current Clinical Trials and Strategies to Overcome Challenges,” Nature Reviews Gastroenterology & Hepatology 22 (2025): 463–480, https://doi.org/10.1038/s41575‐025‐01062‐y.
E. Blass, D. B. Keskin, C. R. Tu, et al., “A Multi‐Adjuvant Personal Neoantigen Vaccine Generates Potent Immunity in Melanoma,” Cell 188 (2025): 5125–5141, https://doi.org/10.1016/j.cell.2025.06.019.
Y. Wang, S. Qiao, J. Wang, et al., “Engineered CpG‐Loaded Nanorobots Drive Autophagy‐Mediated Immunity for TLR9‐Positive Cancer Therapy,” Advanced Materials 36 (2024): 2306248, https://doi.org/10.1002/adma.202306248.
Y. Sato, Y. Goto, N. Narita, and D. S. Hoon, “Cancer Cells Expressing Toll‐Like Receptors and the Tumor Microenvironment,” Cancer Microenvironment 2 (2009): 205–214, https://doi.org/10.1007/s12307‐009‐0022‐y.
T. Hara, K. Tanegashima, R. Takahashi, et al., “A Novel Function of a CXC‐Type Chemokine CXCL14 As a Specific Carrier of CpG DNA Into Dendritic Cells for Activating Toll‐Like Receptor 9‐Mediated Adaptive Immunity,” Blood 128 (2016): 1021, https://doi.org/10.1182/blood.V128.22.1021.1021.
K. Fehér, “Single Stranded DNA Immune Modulators with Unmethylated CpG Motifs: Structure and Molecular Recognition by Toll‐Like Receptor 9,” Current Protein & Peptide Science 20 (2019): 1060–1068.
U. Ohto, T. Shibata, H. Tanji, et al., “Structural Basis of CpG and Inhibitory DNA Recognition by Toll‐Like Receptor 9,” Nature 520 (2015): 702–705, https://doi.org/10.1038/nature14138.
Y. Araie, S. Ohtsuki, S. Park, et al., “Combined Use of Chemically Modified Nucleobases and Nanostructured DNA for Enhanced Immunostimulatory Activity of CpG Oligodeoxynucleotide,” Bioorganic Medicinal Chemistry 29 (2021): 115864.
D. A. Glazier, J. Liao, B. L. Roberts, et al., “Chemical Synthesis and Biological Application of Modified Oligonucleotides,” Bioconjugate Chemistry 31 (2020): 1213–1233, https://doi.org/10.1021/acs.bioconjchem.0c00060.
Z. Lv, X. Guo, R. Zhang, et al., “Dynamic DNA‐Based Nanoadjuvants for TLR9 Clustering and Innate Immune Activation in Dendritic Cells,” Journal of the American Chemical Society 147 (2025): 13545–13555, https://doi.org/10.1021/jacs.5c00481.
Z. N. Huang, L. E. Cole, C. E. Callmann, S. Wang, and C. A. Mirkin, “Sequence Multiplicity Within Spherical Nucleic Acids,” ACS Nano 14 (2020): 1084–1092, https://doi.org/10.1021/acsnano.9b08750.
R. Offersen, S. K. Nissen, T. A. Rasmussen, et al., “A Novel Toll‐Like Receptor 9 Agonist, MGN1703, Enhances HIV‐1 Transcription and NK Cell‐Mediated Inhibition of HIV‐1‐Infected Autologous CD4+ T Cells,” Journal of Virology 90 (2016): 4441–4453, https://doi.org/10.1128/JVI.00222‐16.
M. Jafari, S. Shahryar, S. Mohebbi, et al., “DNA Nanostructures as Promising Anticancer Agents: A Review,” Cancer Treatment and Research Communications 45 (2025): 101029.
K. Sato, J. Lyu, J. van den Berg, et al., “RNA Transcripts Regulate G‐Quadruplex Landscapes Through G‐Loop Formation,” Science 388 (2025): 1225–1231, https://doi.org/10.1126/science.adr0493.
L. Chen, J. Dickerhoff, K. W. Zheng, et al., “Structural Basis for Nucleolin Recognition of MYC Promoter G‐Quadruplex,” Science 388 (2025): adr1752, https://doi.org/10.1126/science.adr1752.
R. Liu, J. Li, B. J. Salena, and Y. Li, “Aptamer and DNAzyme Based Colorimetric Biosensors for Pathogen Detection,” Angewandte Chemie International Edition 64 (2025): 202418725, https://doi.org/10.1002/anie.202418725.
J. Dong, M. P. O'Hagan, and I. Willner, “Switchable and Dynamic G‐Quadruplexes and their Applications,” Chemical Society Reviews 51 (2022): 7631–7661, https://doi.org/10.1039/D2CS00317A.
J. Lopes‐Nunes, P. A. Oliveira, and C. Cruz, “G‐Quadruplex‐Based Drug Delivery Systems for Cancer Therapy,” Pharmaceuticals 14 (2021): 671, https://doi.org/10.3390/ph14070671.
R. Tian, Y. Gao, X. Hu, et al., “Unmodified RNA Sequences Form Unusual Stable G‐Quadruplexes With Potential Anti‐RSV and Anti‐Angiogenesis Applications,” Communications Biology 8 (2025): 474, https://doi.org/10.1038/s42003‐025‐07915‐1.
Q. Yang, X. Wang, Y. Wang, et al., “G4LDB 3.0: A Database for Discovering and Studying G‐Quadruplex and i‐Motif Ligands,” Nucleic Acids Research 53 (2025): D91–D98, https://doi.org/10.1093/nar/gkae835.
M. Miglietta, R. C. Russo, G. Duardo, and G. Capranico, “G‐Quadruplex Binders as Cytostatic Modulators of Innate Immune Genes in Cancer Cells,” Nucleic Acids Research 49 (2021): 6673–6686, https://doi.org/10.1093/nar/gkab500.
J. Lin, Z. Gong, Y. Lu, et al., “Recent Progress and Potential of G4 Ligands in Cancer Immunotherapy,” Molecules (Basel, Switzerland) 30 (2025): 1805, https://doi.org/10.3390/molecules30081805.
L. Zhang, J. Zhao, X. Hu, et al., “A Peritumorally Injected Immunomodulating Adjuvant Elicits Robust and Safe Metalloimmunotherapy Against Solid Tumors,” Advanced Materials 34 (2022): 2206915, https://doi.org/10.1002/adma.202206915.
Z. Yang, H. Liu, S. Li, et al., “Temporally Programmed STING Nanoadjuvant Delivery Unlocks Synergistic Chemotherapy‐Induced Antitumor Immunity,” Science Advances 11 (2025): adw0797, https://doi.org/10.1126/sciadv.adw0797.
S. Chattopadhyay, Y. Liu, Z. Fang, et al., “Synthetic Immunogenic Cell Death Mediated by Intracellular Delivery of STING Agonist Nanoshells Enhances Anticancer Chemo‐Immunotherapy,” Nano Letters 20 (2020): 2246–2256, https://doi.org/10.1021/acs.nanolett.9b04094.
Y. Tian, H. Tian, B. Li, C. Feng, and Y. Dai, “An Ultrasound‐Triggered STING Pathway Nanoagonist for Enhanced Chemotherapy‐Induced Immunogenic Cell Death,” Small 20 (2024): 2309850.
S. Zhang, H. X. Sun, L. X. Wang, et al., “Real‐Time Monitoring of DNA G‐Quadruplexes in Living Cells With a Small‐Molecule Fluorescent Probe,” Nucleic Acids Research 46 (2018): 7522–7532, https://doi.org/10.1093/nar/gky665.
K. Murata, K. Harayama, M. Shimoda, et al., “Improvement of the Nuclease Resistance and Immunostimulatory Activity of CpG Oligodeoxynucleotides by Conjugation to Sugar‐Immobilized Gold Nanoparticles,” Bioconjugate Chemistry 35 (2024): 804–815, https://doi.org/10.1021/acs.bioconjchem.4c00145.
Z. Zhao, M. Li, J. Zeng, et al., Bioactive Materials 12 (2021): 214.
M. Jeon, M. V. Halbert, Z. R. Stephen, and M. Zhang, “Iron Oxide Nanoparticles as T1 Contrast Agents for Magnetic Resonance Imaging: Fundamentals, Challenges, Applications, and Prospectives,” Advanced Materials 33 (2021): 1906539, https://doi.org/10.1002/adma.201906539.
D. Sant'Angelo, G. Descamps, V. Lecomte, et al., “Therapeutic Approaches With Iron Oxide Nanoparticles to Induce Ferroptosis and Overcome Radioresistance in Cancers,” Pharmaceuticals 18 (2025): 325, https://doi.org/10.3390/ph18030325.
M. Adrian, B. Heddi, and A. T. Phan, “NMR spectroscopy of G‐quadruplexes,” Methods (San Diego, Calif) 57 (2012): 11–24, https://doi.org/10.1016/j.ymeth.2012.05.003.
S. Paramasivan, I. Rujan, and P. H. Bolton, “Circular Dichroism of Quadruplex DNAs: Applications to Structure, Cation Effects and Ligand Binding,” Methods (San Diego, Calif) 43 (2007): 324–331, https://doi.org/10.1016/j.ymeth.2007.02.009.
K. Lee, Z. N. Huang, C. A. Mirkin, and T. W. Odom, “Endosomal Organization of CpG Constructs Correlates With Enhanced Immune Activation,” Nano Letters 20 (2020): 6170–6175, https://doi.org/10.1021/acs.nanolett.0c02536.
M. Y. Jung, M. H. Son, S. H. Kim, D. Cho, and T. S. Kim, “IL‐32γ Induces the Maturation of Dendritic Cells With Th1‐ and Th17‐Polarizing Ability Through Enhanced IL‐12 and IL‐6 Production,” The Journal of Immunology 186 (2011): 6848–6859, https://doi.org/10.4049/jimmunol.1003996.
L. Li, L. Jiang, S. Mao, and J. Ye, “TLR9 Knockdown Alleviates Sepsis via Disruption of MyD88/NF‐κB Pathway Activation,” Critical Reviews in Immunology 44 (2024): 15–24, https://doi.org/10.1615/CritRevImmunol.2023050273.
B. Jawad, L. Poudel, R. Podgornik, N. F. Steinmetz, and W. Y. Ching, “Molecular Mechanism and Binding Free Energy of Doxorubicin Intercalation in DNA,” Physical Chemistry Chemical Physics 21 (2019): 3877–3893, https://doi.org/10.1039/C8CP06776G.
Y. Chai, F. Feng, Q. Li, et al., “One‐Pot Synthesis of High‐Quality Bimagnetic Core/Shell Nanocrystals With Diverse Exchange Coupling,” Journal of the American Chemical Society 141 (2019): 3366–3370, https://doi.org/10.1021/jacs.8b12888.
Y. Xue, J. Liu, K. Zheng, Z. Kan, Y. Hao, and Z. Tan, “Kinetic and Thermodynamic Control of G‐Quadruplex Folding,” Angewandte Chemie International Edition 50 (2011): 8046–8050, https://doi.org/10.1002/anie.201101759.
E. R. Radu, A. Semenescu, and S. I. Voicu, “Recent Advances in Stimuli‐Responsive Doxorubicin Delivery Systems for Liver Cancer Therapy,” Polymers 14 (2022): 5249, https://doi.org/10.3390/polym14235249.
A. Arta, J. B. Larsen, A. Z. Eriksen, et al., “Cell Targeting Strategy Affects the Intracellular Trafficking of Liposomes Altering Loaded Doxorubicin Release Kinetics and Efficacy in Endothelial Cells,” International Journal of Pharmaceutics 588 (2020): 119715, https://doi.org/10.1016/j.ijpharm.2020.119715.
W. Chen, F. Li, Y. Tang, et al., “Stepwise pH‐Responsive Nanoparticles for Enhanced Cellular Uptake and on‐Demand Intracellular Release of Doxorubicin,” International Journal of Nanomedicine 12 (2017): 4241–4256, https://doi.org/10.2147/IJN.S129748.
M. Zhu, M. Yang, J. Zhang, et al., “Immunogenic Cell Death Induction by Ionizing Radiation,” Frontiers Immunology 12 (2021): 705361.
D. V. Krysko, A. D. Garg, A. Kaczmarek, O. Krysko, P. Agostinis, and P. Vandenabeele, “Immunogenic Cell Death and DAMPs in Cancer Therapy,” Nature Reviews Cancer 12 (2012): 860–875, https://doi.org/10.1038/nrc3380.
H. Ishikawa, Z. Ma, and G. N. Barber, “STING Regulates Intracellular DNA‐Mediated, Type I Interferon‐Dependent Innate Immunity,” Nature 461 (2009): 788–792, https://doi.org/10.1038/nature08476.
B. C. Zhang, A. Pedersen, L. S. Reinert, et al., “STING Signals to NF‐κB From Late Endolysosomal Compartments Using IRF3 as an Adaptor,” Nature Immunology 26 (2025): 1916–1930, https://doi.org/10.1038/s41590‐025‐02283‐8.
S. K. Wculek, F. J. Cueto, A. M. Mujal, I. Melero, M. F. Krummel, and D. Sancho, “Dendritic Cells in Cancer Immunology and Immunotherapy,” Nature Reviews Immunology 20 (2020): 7–24, https://doi.org/10.1038/s41577‐019‐0210‐z.
S. Dikiy and A. Y. Rudensky, “Principles of Regulatory T Cell Function,” Immunity 56 (2023): 240–255, https://doi.org/10.1016/j.immuni.2023.01.004.
G. Li, S. Li, Y. Jiang, T. Chen, and Z. An, “Unleashing the Power of Immune Checkpoints: A New Strategy for Enhancing Treg Cells Depletion to Boost Antitumor Immunity,” International Immunopharmacology 147 (2025): 113952, https://doi.org/10.1016/j.intimp.2024.113952.
J. Fucikova, L. Kasikova, I. Truxova, et al., “Relevance of the Chaperone‐Like Protein Calreticulin for the Biological Behavior and Clinical Outcome of Cancer,” Immunology Letters 193 (2018): 25–34, https://doi.org/10.1016/j.imlet.2017.11.006.
S. Zhang, H. Zhu, X. Peng, et al., “Efficient Artificial T Cell Therapy for Bacterial‐Colonized Tumors,” Advanced Materials 37 (2025): 2503087, https://doi.org/10.1002/adma.202503087.
Grant Information: 22377128 National Natural Science Foundation of China; 22177114 National Natural Science Foundation of China; 21977096 National Natural Science Foundation of China; YJKYYQ20210010 Chinese Academy of Sciences; L234057 Natural Science Foundation of Beijing Municipality
Contributed Indexing: Keywords: G‐quadruplex CpG; abscopal effect; chemoimmunotherapy; multi‐pathway immune activation; tumor microenvironment reprogramming
Substance Nomenclature: 80168379AG (Doxorubicin)
0 (Toll-Like Receptor 9)
0 (Oligodeoxyribonucleotides)
Entry Date(s): Date Created: 20260325 Date Completed: 20260925 Latest Revision: 20260925
Update Code: 20260926
DOI: 10.1002/adma.72908
PMID: 41879352
Βάση Δεδομένων: MEDLINE
Περιγραφή
ISSN:1521-4095
DOI:10.1002/adma.72908